Breast cancers exhibit high heterogeneity, leading to distinct therapeutic approaches, such as endocrine therapy for HR+ BCs, targeted therapy with anti-HER-2 monoclonal antibodies for HEBCs, and NST mainly for TNBCs (3). Here, ERBB2 is linked to breast carcinoma.